Some studies have indicated that mTORC2 is critical for the progression of PCa when PTEN is deleted in the prostate epithelium, while mTORC2 activity is not essential in the normal prostate epithelium,33 indicating that mTORC2‐specific inhibitors may be promising therapeutic agents for PCa. The gene discussed is PTEN; the disease is posterior cortical atrophy.